Macrocyclic compounds and methods of treatment
Patent Number: US9023875
Executive Summary:
General Description:
Cancer is characterized by excessive proliferation of malignant cells. It is therefore critical to identify novel pharmacophores with anti-proliferative properties. This invention exploited the biodiversity of the marine environment and found a novel anti-proliferative compound with high bioactivity and selectivity. The compound is a metabolite purified from marine cyanobacteria.
Strengths:
Weaknesses:
Disclosure:
Disclosure Links:
https://www.sbir.gov/sbirsearch/detail/1029789
http://www.oceanyxpharma.com/
Patent Status:
Inventor Bio: Hendrik Luesch
http://pharmacy.ufl.edu/faculty/hendrikluesch/
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Active
- Patent Link: https://patents.google.com/patent/US9023875/
- Research Institute: University of Florida
- Disease Focus: Proliferative disorders
- Basis of Invention: Natural pharmacophore with therapeutic activity
- How it works: Largazole is a macrocyclic metabolite purified from marine cyanobacteria. It has been shown to have anti-proliferative properties and is therefore a suitable compound to treat proliferative diseases. In addition, largazole also inhibits histone deacetylase (HDAC) and can therefore be a treatment for HDAC mediated disorders
- Lead Challenge Inventor: Hendrik Luesch
- Inventors: Hendrik Luesch, Taori Kanchan, Valerie Paul
- Development Stage: Pre-clinical
- Novelty:
- Natural product, novel chemical scaffold with antiproliferative properties
- Clinical Applications:
- Therapeutic against proliferative diseases
General Description:
Cancer is characterized by excessive proliferation of malignant cells. It is therefore critical to identify novel pharmacophores with anti-proliferative properties. This invention exploited the biodiversity of the marine environment and found a novel anti-proliferative compound with high bioactivity and selectivity. The compound is a metabolite purified from marine cyanobacteria.
Strengths:
- Natural compound
- Nanomolar activity
- High selectivity
- Feasible scale-up for mass production
Weaknesses:
- Mechanism unknown
Disclosure:
- Oceanyx Pharmaceuticals has been awarded an SBIR Phase I grant to further develop this intellectual property for commercial use. However, this technology has not been licensed or optioned by the University of Florida. There are opportunities for the winning team to partner with Oceanyx Pharmaceuticals to bring this technology to market.
Disclosure Links:
https://www.sbir.gov/sbirsearch/detail/1029789
http://www.oceanyxpharma.com/
Patent Status:
- Filing date: 2013-01-22
Inventor Bio: Hendrik Luesch
http://pharmacy.ufl.edu/faculty/hendrikluesch/
